CRC
PCRX icon

Curi RMB Capital’s Pacira BioSciences PCRX Stock Holding History

Curi RMB Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,938
Closed -$1.38M – 631
2020
Q3 		$1.38M Sell
22,938
-5,967
-21% -$347K 0.06% 244
2020
Q2 		$1.52M Buy
+28,905
New +$1.21M 0.07% 240

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Curi RMB Capital's PCRX Position: Q4 2020 in Review

Curi RMB Capital sold out of Pacira BioSciences (PCRX) in Q4 2020, closing a stake of 22,938 shares — an estimated $1.38M sold.

Curi RMB Capital first reported a position in PCRX in Q2 2020 and held it in 2 quarters. The position peaked at $1.52M in Q2 2020. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2020.

  • Curi RMB Capital reported no remaining Pacira BioSciences position as of Q4 2020 after selling out during the quarter.
  • Curi RMB Capital sold 22,938 Pacira BioSciences shares in Q4 2020, an estimated $1.38M.
  • Curi RMB Capital first reported a position in Pacira BioSciences in Q2 2020 and held it in 2 quarters.
  • Curi RMB Capital's Pacira BioSciences position peaked at $1.52M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2020.

Based on Curi RMB Capital's 13F filing for Q4 2020, filed 11 Feb 2021.